Use of microbial strain in preparation of drug for preventing or treating metabolic diseases

By activate GPR120, MC4R and APJ targets using Nosocomiicoccus massiliensis, the problems of poor effectiveness of existing weight loss drugs and limitations in intestinal microbiota research have been solved, effective treatment of obesity and metabolic diseases have been achieved, and weight and blood sugar have been significantly reduced. Improve lipid metabolism and liver function.

WO2024251030A1PCT designated stage expired Publication Date: 2024-12-12IBIOME BIOTECHNOLOGY CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/096555
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-03-19
Filing Date
2024-05-31
Publication Date
2024-12-12

AI Technical Summary

Technical Problem

Existing weight loss drugs are not effective in treating obesity and metabolic diseases, and have serious adverse reactions. Intestinal flora research mainly focuses on Bifidobacterium and Lactobacillus, and lack the development of other strains, especially Nosocomiicococcus There are few studies on metabolism of massiliensis.

Method used

Nosocomiicoccus massiliensis is used as a microbial strain to develop drugs for the prevention and treatment of obesity, diabetes and related metabolic diseases. By activating GPR120, MC4R and APJ targets, it reduces weight, blood sugar and lipid metabolism indicators and improves non-alcoholic fatty liver symptoms .

Benefits of technology

Significantly reducing the weight, blood sugar and lipid metabolism-related indicators in obese mice, improving insulin sensitivity and liver function, provides a safe and effective new way to treat obese and metabolic diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024096555_12122024_PF_FP_ABST
    Figure CN2024096555_12122024_PF_FP_ABST
Patent Text Reader

Abstract

A use of a microbial strain in preparation of a drug for preventing or treating metabolic diseases, wherein the microbial strain belongs to species Nosocomiicoccus massiliensis, and the metabolic diseases are diabetes, obesity, obesity-related diseases, and metabolic syndrome. Nosocomiicoccus massiliensis can be used for remarkably activating targets GPR120, MC4R and APJ for treating obese diabetics; the body weight, blood sugar, lipid metabolism related indexes (triglyceride, total cholesterol, and low-density lipoprotein-cholesterol) and symptoms of non-alcoholic fatty liver disease (triglyceride, total cholesterol, low-density lipoprotein-cholesterol, and free fatty acid in the liver) of obese mice can be reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Use of microbial strains in preparing medicines for preventing or treating metabolic diseases Technical Field

[0001] The present invention relates to the field of microorganisms, in particular to Nosocomiicoccus massiliensis and application thereof in medicines for preventing and treating metabolic diseases. Background Art

[0002] Obesity is a global public health issue, leading to numerous health complications and comorbidities, including type 2 diabetes, hyperlipidemia, fatty liver disease, and cardiovascular disease. The Chinese obesity drug market grew from RMB 260 million in 2016 to RMB 1.9 billion in 2020, achieving a compound annual growth rate of 64.6%. Driven by factors such as the increasing prevalence of obesity, heightened awareness of weight management, and the launch of new weight loss drugs, the Chinese obesity drug market is projected to reach RMB 8.7 billion in 2025 and continue to experience rapid growth, reaching nearly RMB 15 billion by 2030. However, some current weight loss drugs fail to achieve the desired effect, while others can cause serious adverse reactions. Therefore, the development of safer and more effective weight loss drugs is urgently needed.

[0003] Recent research has shown that the gut microbiome is closely linked to metabolic diseases. In 2004, Professor Jeffery Gordon of the University of Washington published a paper demonstrating the inextricable link between obesity, diabetes, and other conditions and gut microbiome imbalance. Subsequent studies have shown that the gut microbiome can influence food intake and absorption, gastrointestinal hormone levels, and fat metabolism, thereby impacting obesity-related metabolic diseases. Furthermore, probiotics have the potential to treat obesity, diabetes, and non-alcoholic fatty liver disease. However, current research has largely been limited to first-generation probiotics such as Bifidobacterium and Lactobacillus. With the rise of gut microbiome culturing, a large number of gut strains have been discovered, laying the foundation for the development of more effective second-generation probiotic drugs.

[0004] Nosocomiicoccus massiliensis is a Gram-positive coccus originally isolated from a hospital setting. It belongs to the phylum Firmicutes, family Staphylococcaceae, and genus Nosocomiicoccus. As a new species discovered in 2013, it has received relatively little research, especially regarding its metabolic properties. Based on this, the present invention provides a second-generation probiotic drug, Nosocomiicoccus massiliensis, that can prevent and treat obesity-related metabolic diseases. Technical Solutions

[0005] The purpose of the present invention is to solve the above-mentioned deficiencies in the prior art and provide Nosocomiicoccus massiliensis and its use in medicines for preventing and treating metabolic diseases.

[0006] The present invention is achieved through the following technical solutions:

[0007] The present invention relates to use of a microbial strain in preparing a medicine for preventing or treating metabolic diseases. The microbial strain belongs to the species Nosocomiicoccus massiliensis. The metabolic diseases are diabetes, obesity and obesity-related diseases, and metabolic syndrome.

[0008] Throughout this specification, the term "diabetes mellitus" encompasses all forms of diabetes, which, as described above, are characterized by metabolic disorders and abnormally high blood sugar levels (hyperglycemia) due to insufficient insulin levels. This term encompasses type 1 diabetes (T1D), type 2 diabetes (T2D), gestational diabetes mellitus (GDM), and impaired glucose tolerance (IGT). Type 1 diabetes, caused by autoimmune or idiopathic causes, is characterized by the complete destruction of pancreatic islet function. It primarily occurs in children and adolescents and requires insulin therapy for satisfactory efficacy; otherwise, it can be life-threatening. Type 2 diabetes is a multifactorial syndrome characterized by abnormal carbohydrate / fat metabolism, typically including hyperglycemia, hypertension, and abnormal cholesterol levels. Type 2 diabetes is caused by an ineffective insulin response (low insulin binding to receptors), so it is important to monitor not only fasting blood sugar levels but also two hours after a meal, with particular emphasis on pancreatic islet function testing. Diabetes during pregnancy can occur in two ways: one is diagnosed with diabetes before pregnancy, known as "diabetes complicated by pregnancy." The other is normal glucose metabolism or underlying impaired glucose tolerance before pregnancy, which develops or is diagnosed during pregnancy. This is also known as "gestational diabetes mellitus (GDM)." Over 80% of pregnant women with diabetes have GDM. Impaired glucose tolerance (IGT) is a prediabetic condition associated with insulin resistance and an increased risk of cardiovascular disease. According to the World Health Organization and American Diabetes Association criteria, glucose intolerance is defined as a two-hour glucose level of 140-199 mg / dL (7.8 to 11.0 mmol) on a 75 g oral glucose tolerance test. Patients are considered to have IGT when their glucose level is immediately elevated but below the criteria for type 2 diabetes two hours later. Fasting glucose levels may be normal or slightly elevated. IGT can precede the onset of type 2 diabetes by many years. IGT is also a risk factor for mortality.

[0009] It should be noted that the above-mentioned pharmaceutical uses for diabetes include but are not limited to the treatment or prevention of type 1 diabetes (T1D), type 2 diabetes (T2D), gestational diabetes mellitus (GDM) and impaired glucose tolerance (IGT).

[0010] Throughout this specification, the term "obesity" is associated with body mass index (BMI). BMI (calculated by weight in kilograms divided by height in meters squared) is the most commonly accepted method for calculating overweight and / or obesity. A BMI over 25 is considered overweight. A BMI of 30 or higher is defined as obese, a BMI of 35 or higher as severe comorbidity obesity, and a BMI of 40 or higher as morbid obesity.

[0011] As described above, the term "obesity" as used herein includes overweight, obesity, comorbid obesity, and morbid obesity. Therefore, the term "obesity" as used herein can be defined as a subject having a BMI greater than or equal to 25. In some embodiments, suitably, the BMI of an obese subject can be greater than or equal to 30, suitably 35, suitably 40.

[0012] While the compositions of the present invention are particularly suitable for patients who suffer from both diabetes and obesity, they are also suitable for patients who suffer from diabetes but are not obese, and are also suitable for obese patients who have risk factors for diabetes but are not yet in a diabetic state. It is expected that obese people (but not diabetic) may limit the metabolic consequences of their obesity, namely the development of diabetes or at least insulin resistance.

[0013] In addition, the Nosocomiicoccus massiliensis strains used in the present invention can be used to treat metabolic syndrome in mammals. Metabolic syndrome is a general term for medical conditions that increase the risk of cardiovascular disease and diabetes. Metabolic syndrome is also known as metabolic syndrome X, syndrome X, insulin resistance syndrome, Reaven's syndrome, or CHAOS syndrome (Australia).

[0014] There is currently no single accepted definition of metabolic syndrome.

[0015] The World Health Organization (1999) criteria require the presence of diabetes, glucose intolerance, fasting glucose intolerance, or insulin resistance, and two of the following: blood pressure: ≥140 / 90 mmHg; dyslipidemia: triglycerides (TG): ≥1.695 mmol / L, high-density lipoprotein cholesterol (HDL-C) ≤0.9 mmol / L (males), ≤1.0 mmol / L (females); central obesity: waist:hip ratio >0.90 (males), >0.85 (females), and / or body mass index >30 kg / m 2 ; Microalbuminuria: urinary albumin excretion rate ≥20 mg / min, or albumin:creatinine ratio ≥30 mg / g.

[0016] The European Insulin Resistance Study Group (1999) requires that insulin resistance be defined as a fasting insulin value of 25% or more in non-diabetic individuals, plus two or more of the following: central obesity: waist circumference ≥94 cm (males), ≥80 cm (females); dyslipidemia: TG ≥2.0 mmol / L, and / or HDL-C <1.0 mg / dL, or being treated for dyslipidemia; hypertension: blood pressure ≥140 / 90 mmHg, or being treated with antihypertensive drugs; fasting blood glucose ≥6.1 mmol / L.

[0017] The National Cholesterol Education Program (NCEP) Adult Treatment Scenario III (2001) requires at least three of the following: central obesity: waist circumference ≥102 cm or 40 inches (male), ≥88 cm or 36 inches (female); dyslipidemia: TG ≥1.695 mmol / L (150 mg / dl); dyslipidemia: HDL-C <40 mg / dL (male), <50 mg / dL (female); blood pressure: ≥130 / 85 mmHg; fasting blood glucose ≥6.1 mmol / L (110 mg / dl).

[0018] Preferably, the obesity-related disease includes at least one of the following diseases: cardiovascular disease, hyperlipidemia, insulin resistance syndrome and steatohepatitis.

[0019] Examples of cardiovascular diseases that can be treated using the microbial strain of the species Nosocomiicoccus massiliensis according to the present invention include aneurysm, angina pectoris, atherosclerosis, cerebrovascular accident (stroke), cerebrovascular disease, congestive heart failure (CHF), coronary heart disease, myocardial infarction (heart attack), and peripheral vascular disease.

[0020] An aneurysm is a localized, blood-filled dilation (ballooning) of a blood vessel caused by a diseased or weakened vessel wall. Aneurysms most commonly occur in the arteries at the base of the brain (the cerebral arterial circle) and the aorta (the main artery leaving the heart; this is called an aortic aneurysm). As an aneurysm grows, the risk of rupture increases, which can lead to severe bleeding or other complications, including sudden death.

[0021] Angina pectoris (often called angina) is severe chest pain caused by myocardial ischemia (lack of blood and, therefore, oxygen) and usually due to blockage or spasm of the coronary arteries (blood vessels of the heart). Coronary artery disease (the main cause of angina) is caused by atherosclerosis of the heart's arteries.

[0022] Atherosclerosis is a condition in which the walls of arteries thicken due to the accumulation of fatty substances, such as cholesterol. It is a syndrome affecting arterial blood vessels and is a chronic inflammatory response in the arterial wall, largely due to the accumulation of white blood cells called macrophages. This is facilitated by low-density (particularly small) lipoproteins (plasma proteins that carry cholesterol and triglycerides), rather than the proper removal of fat and cholesterol from macrophages by functional high-density lipoproteins (HDL). Often referred to as hardening of the arteries or "furring," atherosclerosis typically results from the formation of multiple plaques within the arteries.

[0023] A stroke is a rapid loss of brain function caused by a disruption in the blood supply to the brain. This can be due to ischemia (lack of blood supply) caused by a blood clot or embolism, or due to bleeding. As a result, the affected area of ​​the brain cannot function, leading to loss of movement of one or more limbs on one side of the body, difficulty understanding or describing speech, or loss of vision on one side, and ultimately death.

[0024] Cerebrovascular disease (CVD) is a group of brain disorders associated with disorders of the blood vessels supplying the brain. Hypertension is the most important cause of damage to the endothelium, the inner membrane of blood vessels that contacts the underlying collagen layer. Platelets accumulate in this underlying collagen layer, initiating a repair process that is not always complete or perfect. Persistent hypertension permanently alters vascular structure, causing narrowing, stiffness, deformation, and unevenness, making it more susceptible to fluctuations in blood pressure. A drop in blood pressure during sleep can significantly reduce blood flow in narrowed vessels, leading to morning ischemic strokes, while a sudden rise in blood pressure can cause blood vessels to rupture, leading to intracranial hemorrhage during daytime excitement. Cerebrovascular disease primarily affects the elderly, those with diabetes, smokers, or those with ischemic heart disease. All diseases associated with arterial dysfunction can be categorized under the term macrovascular disease. This is an oversimplification, as it allows arteries to become blocked by fatty deposits or blood clots. Consequences of CVD can include stroke, or sometimes even hemorrhagic stroke. During a cerebrovascular accident, ischemia or other vascular dysfunction can affect one's condition.

[0025] Heart failure is a general term for a physiological state in which cardiac output is insufficient to meet the body's needs. This can occur in the presence of low cardiac output (often referred to as "congestive heart failure"). Common causes of heart failure include myocardial infarction and other forms of ischemic heart disease, hypertension, valvular heart disease, and cardiomyopathy.

[0026] Coronary artery disease (or coronary artery heart disease) is the inability of the coronary artery circulation to properly supply the heart muscle and surrounding tissues. It is often equated with atherosclerotic coronary artery disease, but coronary artery disease can be attributed to other causes, such as coronary vasospasm. Stenosis may be caused by spasm.

[0027] A myocardial infarction (commonly known as a heart attack) occurs when the blood supply to part of the heart is blocked, causing certain heart cells to die. This is most often attributed to blockage (occlusion) of a coronary artery following the rupture of a vulnerable atherosclerotic plaque (an unstable accumulation of lipids (such as cholesterol) and white blood cells (particularly macrophages) in the artery wall). The resulting ischemia (restricted blood supply) and oxygen deficiency, if left untreated long enough, can lead to myocardial damage and / or necrosis (infarction).

[0028] Peripheral vascular disease (PVD), also known as peripheral arterial disease (PAD) or peripheral arterial occlusive disease (PAOD), encompasses all conditions caused by occlusion of the large arteries in the arms and legs. PVD can be attributed to atherosclerosis, an inflammatory process leading to stenosis, embolism, or thrombosis, which results in acute or chronic ischemia (lack of blood supply), typically in the legs.

[0029] It is contemplated within the scope of the present invention that the embodiments of the present invention may be combined, such that any combination of features described herein is also encompassed within the scope of the present invention. In particular, it is contemplated within the scope of the present invention that any therapeutic effect of the bacteria may be simultaneously embodied.

[0030] Preferably, the functional bacterial agent or drug is used for at least one of the following purposes:

[0031] Preventing or treating obesity-induced diabetes; preventing or treating type II diabetes; activating GPR120, MC4R and / or APJ; reducing the body weight of a mammal; reducing the weight of adipose tissue and / or liver in a mammal; lowering fasting blood glucose in a mammal; lowering plasma glucose in a mammal; lowering the area under the oral glucose tolerance curve in a mammal; lowering the area under the insulin tolerance curve in a mammal; improving abnormal insulin sensitivity in a mammal; lowering the level of at least one of the following indicators in the blood of a mammal: total cholesterol, triglycerides, low-density lipoprotein-cholesterol; lowering the level of at least one of the following indicators in the liver of a mammal: total cholesterol, triglycerides, low-density lipoprotein-cholesterol, free fatty acids.

[0032] Preferably, the microbial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 98.65%, 99%, 99.5%, 99.63%, 99.9%, or 100% identical to SEQ ID NO: 1 or 2.

[0033] Preferably, the functional bacterial agent or medicine further includes a pharmaceutically acceptable excipient, carrier, auxiliary material and / or vehicle.

[0034] Examples of excipients, carriers, adjuvants, vehicles include, but are not limited to, anti-adherents, binders, coatings, compression aids, disintegrants, dyes, lubricants, emulsifiers, fillers (diluents), film formers or coatings, flavorings, fragrances, glidants (flow enhancers), lubricants, adsorbents, suspending or dispersing agents, or sweeteners. Exemplary excipients, carriers, adjuvants, and vehicles include, but are not limited to, butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (monohydrogen), calcium stearate, croscarmellose, cross-linked polyvinyl pyrrolidone, citric acid, cross-linked povidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methylparaben, microcrystalline cellulose, polyethylene glycol, povidone, pregelatinized starch, propylparaben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethylcellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.

[0035] The drug can be prepared in the form of an injectable preparation or an oral preparation. The injectable preparations are classified by physical state into liquid injections, powders for injection, and tablets for injection; and by injection site into intradermal injections, subcutaneous injections, intramuscular injections, intravenous injections, and spinal injections. The solvent for the injectable preparations is preferably water for injection or physiological saline.

[0036] Formulations for oral use include tablets containing the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients. These excipients may be, for example, inert diluents or fillers (e.g., sucrose, sorbitol, sugar, mannitol, microcrystalline cellulose, starch including potato starch, calcium carbonate, sodium chloride, lactose, calcium phosphate, calcium sulfate, or sodium phosphate); granulating agents and disintegrants (e.g., cellulose derivatives including microcrystalline cellulose, starch including potato starch, croscarmellose sodium, alginates, or alginic acid); binders (e.g., sucrose, glucose, sorbitol, gum arabic, alginic acid, sodium alginate, gelatin, starch, pregelatinized starch, microcrystalline cellulose, magnesium aluminum silicate, sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, ethylcellulose, polyvinyl pyrrolidone, or polyethylene glycol); and lubricants, glidants, and anti-adherents (e.g., magnesium stearate, zinc stearate, stearic acid, silicon dioxide, hydrogenated vegetable oil, or talc). Formulations for oral use may also be in the form of chewable tablets, or in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent (e.g., potato starch, lactose, microcrystalline cellulose, calcium carbonate, calcium phosphate or kaolin), or in the form of soft gelatin capsules in which the active ingredient is mixed with water or an oil medium (e.g., peanut oil, liquid paraffin or olive oil). Powders, granules and pills can be prepared using the ingredients mentioned above under tablets or capsules in a conventional manner using, for example, a mixer, fluidized bed equipment or spray drying equipment.

[0037] Other pharmaceutically acceptable excipients for oral formulations include, but are not limited to, colorants, flavorings, plasticizers, humectants, and buffers. Formulations for oral use may also be in the form of chewable tablets, or hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent (e.g., potato starch, lactose, microcrystalline cellulose, calcium carbonate, calcium phosphate, or kaolin), or soft gelatin capsules in which the active ingredient is mixed with water or an oil medium (e.g., peanut oil, liquid paraffin, or olive oil). Powders, granules, and pills can be prepared using the ingredients mentioned above under tablets or capsules in a conventional manner using, for example, a mixer, fluidized bed apparatus, or spray drying equipment.

[0038] In some embodiments, administration comprises administering an agent described herein intramuscularly, intravenously (e.g., as a sterile solution and in a solvent system suitable for intravenous use), intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrapleurally, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, transperitoneally, subcutaneously, subconjunctivally, intracapsularly, transmucosally, intrapericardially, intraumbilically, intraocularly, orally (e.g., as a tablet, capsule, caplet, gelcap, or syrup), topically (e.g., as a cream, gel, lotion, or ointment), topically, by inhalation, by injection, or by infusion (e.g., continuous infusion as a cream or lipid composition, local perfusion directly bathing target cells, catheterization, lavage).

[0039] Preferably, the functional bacterial agent or drug also includes other drugs that act synergistically with Nosocomiicoccus massiliensis.

[0040] Preferably, the microbial strain is the Nosocomiicoccus massiliensis ibiome006 strain or its progeny strain or subclone strain deposited with the deposit number CCTCC NO: M 2023697, and the Nosocomiicoccus massiliensis ibiome006 strain is deposited in the China Center for Type Culture Collection, located at the China Center for Type Culture Collection, Wuhan University, Bayi Road, Wuchang District, Wuhan City, Hubei Province, and the deposit date is May 6, 2023.

[0041] The present invention also protects the Nosocomiicoccus massiliensis ibiome006 strain deposited with CCTCC NO: M 2023697 or its progeny strain or subclone strain.

[0042] The present invention also protects a medicine comprising the above-mentioned strain and a pharmaceutically acceptable excipient, carrier, auxiliary material and / or vehicle, and / or a combined drug.

[0043] The present invention also protects a pharmaceutical composition comprising the above-mentioned strain and a combined drug, wherein the combined drug is another drug that has a synergistic effect with Nosocomiicoccus massiliensis.

[0044] Preferably, the combination drug is an active ingredient of other hypoglycemic and lipid-lowering drugs, such as GLP-1 receptor agonists or GLP-1 mimetics, GIP receptor agonists, dipeptidyl peptidase-4 inhibitors, metformin, etc., specifically selected from exenatide, liraglutide, semaglutide, oral dosage form of semaglutide, benaglutide, lixisenatide and exenatide weekly preparation, etc.

[0045] The dosage form of the composition of the present invention is granules, capsules, tablets, powders, oral liquids, suspensions, or emulsions.

[0046] The effective dose of the present invention is that the total number of viable bacteria of Nosocomiicoccus massiliensis as the main active ingredient in the live bacteria preparation is 10 6 -10 14 CFU.

[0047] The medication cycle is based on the ability to achieve the desired effect, including but not limited to 1-3 times a day, 3-7 days a week, etc., and is also related to the effective concentration of the specific preparation.

[0048] The present invention also protects a starter culture, a functional bacterial agent or a nutritional composition comprising the Nosocomiicoccus massiliensisibiome006.

[0049] A starter culture or functional bacterial agent includes a bacterial solution prepared from the aforementioned Nosocomiicoccus massiliensisibiome006, or a powder or granule obtained by further processing; the starter culture may further contain one or more non-antagonistic microbial agents, selected from one or more of Christensenella, Parabacteroides, Akkermansia muciniphila, and Bacteroides thetaiotaomicron to prepare a composite bacterial agent.

[0050] Effective bacterial concentration and viable bacterial count are 10 6 -10 14 CFU.

[0051] Fermentation agents or functional bacterial agents can also be used as functional foods and nutritional products.

[0052] A nutritional composition comprising the above-mentioned Nosocomiicoccus massiliensisibiome006 and a food, a nutraceutical, a supplement, a probiotic or a symbiotic bacteria.

[0053] The food includes the above-mentioned Nosocomiicoccus massiliensisibiome006 and auxiliary substances that realize the functions of the food, and its forms include but are not limited to "dietary supplements", "fermented foods", etc.

[0054] The dietary supplement comprises the bacterial solution prepared from the aforementioned Nosocomiicoccus massiliensisibiome006 or the powder obtained by further processing, and is further processed by adding nutrients such as cellulose, vitamins, and minerals.

[0055] The fermented foods include dairy products, soy products, or fruit and vegetable products. The dairy products include milk, sour cream, or cheese. The soy products include soy milk, fermented black beans, or soybean paste. The fruit and vegetable products include cucumber, carrot, beet, celery, or cabbage products.

[0056] Probiotics are live microorganisms that, when provided in appropriate amounts, confer a beneficial effect on the health of the host organism.

[0057] The commensal bacteria refer to foods containing a mixture of prebiotics and probiotics. They generally contain prebiotic components that are beneficial to growth and / or metabolic activity, and generally the probiotic effects of a combination of, for example, but not limited to, Nosocomiicoccus massiliensisibiome006 and oligofructose or oligogalactose. Beneficial effects

[0058] The Nosocomiicoccus massiliensis of the present invention can significantly activate GPR120, MC4R and APJ, targets for treating obesity and diabetes; and can reduce the body weight, blood sugar, lipid metabolism-related indicators (triglycerides, total cholesterol, low-density lipoprotein-cholesterol) and symptoms of non-alcoholic fatty liver disease (triglycerides, total cholesterol, low-density lipoprotein-cholesterol, free fatty acids in the liver) of obese mice. Biological Deposits

[0059] Nosocomiicoccus massiliensisibiome006, deposit date May 6, 2023, deposit location is China Center for Type Culture Collection, address is China Center for Type Culture Collection, Wuhan University, Bayi Road, Wuchang District, Wuhan City, Hubei Province, deposit number is CCTCC NO: M 2023697. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] FIG1 shows the microscopic (A) and macroscopic (B) morphologies of the isolated strains.

[0061] FIG2 shows the detection results of GPR120 (A), MC4R (B), and APJ (C) activation at the cellular level in N. massiliensis.

[0062] FIG3 shows the effect of N. massiliensis on the body weight of mice in the high-fat diet-induced obese mouse treatment experiment of Example 3.

[0063] FIG4 shows the effects of N. massiliensis on blood glucose (A fasting blood glucose, B insulin tolerance, C oral glucose tolerance, D plasma glucose) in the high-fat diet-induced obese mouse treatment experiment of Example 3.

[0064] FIG5 shows the effects of N. massiliensis on lipid metabolism (A subcutaneous fat weight, B plasma total cholesterol, C plasma triglycerides, D plasma low-density lipoprotein cholesterol) in the high-fat diet-induced obese mouse treatment experiment of Example 3.

[0065] FIG6 shows the effects of N. massiliensis on liver function and fatty liver (A liver weight, B liver total cholesterol, C liver triglycerides, D liver low-density lipoprotein cholesterol, E liver free fatty acids) in the high-fat diet-induced obese mouse treatment experiment of Example 3.

[0066] FIG7 shows the effect of N. massiliensis on the body weight of mice in the high-fat diet-induced obesity prevention experiment in Example 4.

[0067] FIG8 shows the effects of N. massiliensis on blood glucose (A fasting blood glucose, B plasma glucose, C oral glucose tolerance, D insulin tolerance, E area under the insulin tolerance curve) in the high-fat diet-induced obesity prevention experiment in Example 4.

[0068] FIG9 shows the effects of N. massiliensis on lipid metabolism (A abdominal fat weight, B liver weight, C plasma total cholesterol, D plasma triglycerides) in the high-fat diet-induced obesity prevention experiment in Example 4. Best Mode for Carrying Out the Invention

[0069] For a better understanding of the present invention, the present invention is further described below in conjunction with embodiments and drawings. The following embodiments are merely illustrative of the present invention and are not intended to limit the present invention.

[0070] Example 1: Isolation and identification of Nosocomiicoccus massiliensis

[0071] (1) Isolation of Nosocomiicoccus massiliensis

[0072] The Nosocomiicoccus massiliensis strain of the present invention was isolated from the feces of a healthy female volunteer in Fuyang City, Anhui Province, who had not used antibiotics for a year. After signing an informed consent form for stool collection with the company, the donor collected 2-5 grams of fresh feces and placed them in a sample collection tube containing glycerol. After shaking and homogenization, the processed fecal sample was placed in an ice box and delivered to the laboratory for strain isolation within 24 hours.

[0073] ① Pretreatment of fecal samples: Take 1 mL of the mixture from the sample collection tube containing glycerol and feces and add it to 9 mL of 1X sterile PBS solution. Vortex the mixture and then take 100 μL of the mixture and dilute it step by step to 10 -9 Diluent for plate coating.

[0074] ② Spread 100 μL of the diluted sample onto GAM medium (Solabo, LA4450). After the plate surface is dry, invert and place it in a microaerobic workbench (temperature: 37°C, O2: 5%, CO2: 5%, mixed gas: 90%) for incubation. Incubate for 24-36 hours. Once a single clone grows, purify the single clone by multiple streaking. Perform 16s rRNA sequencing on the purified strain to determine the strain's taxonomic status.

[0075] (2) Identification of Nosocomiicoccus massiliensis

[0076] Bacterial characteristics: The morphology of the isolated strain under a 40x optical microscope after staining is shown in Figure 1A. Under the microscope, after microaerophilic culture in GAM medium at 37°C for 24 h, Gram staining was positive, and the bacteria were spherical with an average diameter of about 0.7 μm.

[0077] Colony characteristics: The growth status of the isolated strain on the plate is shown in Figure 1B. After microaerophilic culture at 37°C in GAM medium for 24 h, the colonies were round, moist, opaque, light yellow, and had neat edges.

[0078] Growth characteristics: The isolated strain can grow under both aerobic and anaerobic conditions, but grows faster under aerobic conditions. The optimal growth temperature is 37°C.

[0079] Biochemical characteristics: The biochemical characteristics of the isolated strains are shown in Table 1 below. In this example, the physiological and biochemical identification of microorganisms was performed using a Haibo Biotechnology bacterial microbiological identification tube.

[0080] Table 1 Biochemical characteristics of strains

[0081] Test Items Test Results L-arabinose-ribose-D-maltose-D-lactose-sucrose-D-glucose-D-fructose-mannose-mannitol-

[0082] Explanation of symbols: “+”, positive; “-”, negative.

[0083] 16S rRNA sequencing: 16S rRNA PCR amplification was performed on the strain using the following system: 12.5 μL of 2✖ Taq Master Mix (Novozymes; P112-01), 1 μL of primer 1 (27F: AGAGTTTGATCCTGGCTCAG), 1 μL of primer 2 (1492R: TACGGCTACCTTGTTACGACTT), 1 μL of liquid culture, and 9.5 μL of ddH₂O. Amplification conditions included initial denaturation at 95°C for 3 min, followed by 35 cycles of denaturation at 95°C for 15 s, annealing at 58°C for 15 s, and extension at 72°C for 30 s, followed by a complete extension at 72°C for 5 min. The amplified product was sequenced by Qingke Biotechnology Co., Ltd., and the resulting 16S rRNA gene sequence (SEQ ID NO. 1) was submitted to the NCBI Basic Local Alignment Search Tool for 16S rRNA gene analysis. The comparison results showed that the strain with the highest similarity was Nosocomiicoccus massiliensis strain NP2 (SEQ ID NO. 2, similarity 99.63%), so this strain belongs to the species Nosocomiicoccus massiliensis and is numbered Nosocomiicoccus massiliensisibiome006.

[0084] Example 2 Screening of Nosocomiicoccus massiliensis activating GPR120, MC4R and APJ at the in vitro cellular level

[0085] GPR120 is a receptor for long-chain unsaturated fats, expressed in multiple tissues throughout the body, with particularly high expression in colonic adipose tissue. It regulates gastrointestinal peptide hormone secretion, thereby influencing appetite and regulating adipocyte development and differentiation, among other physiological functions. GPR120 is closely associated with metabolic diseases such as obesity, diabetes, insulin resistance, and fatty liver.

[0086] MC4R is primarily expressed in hypothalamic neurons and is the terminal gene in the leptin-mediated appetite regulation pathway. α-MSH, derived from proopiomelanocortin, binds to its receptor MC4R in the hypothalamus, producing a physiological effect that suppresses appetite. MC4R regulates food intake and energy expenditure by acting on central proopiomelanocortin (POMC) neurons, sympathetic preganglionic neurons, and interacting with corresponding agonists, thereby improving obesity. Recent studies have shown that activating MC4R in L cells in the peripheral intestine can promote the secretion of GLP-1 and PYY, and also regulate energy metabolism.

[0087] APJ is widely distributed in various tissues and plays a key role in regulating cardiovascular system function.

[0088] In summary, GPR120, MC4R, and APJ are important targets for the treatment of metabolic diseases such as obesity and diabetes.

[0089] (1) Experimental materials:

[0090] Preparation of Nosocomiicoccus massiliensisibiome006 bacterial culture supernatant: Take 100 μL of glycerol bacteria (Nosocomiicoccus massiliensisibiome006 bacteria stored in glycerol) and add it to 2 mL of GAM medium. Incubate the culture in a 37°C incubator for 48 hours. Centrifuge the culture at 12,000 rpm, 4°C, for 10 minutes, and collect the supernatant for cell screening.

[0091] Positive drug: GPR120 positive drug: (Manufacturer: selleck, Catalog No.: GSK13764A); MC4R positive drug: Setmelanotide (Manufacturer: selleck, Catalog No.: RM-493)

[0092] GAM medium control: GAM medium without cultured bacteria

[0093] Blank control: HTLA cells transfected with GPCR-tango plasmid were not treated with any other treatment.

[0094] (2) Experimental methods:

[0095] A. HEK293 cells stably expressing β-arrestin and tTA-luciferase (manufacturer: HTLA; gift from the Institute of Immunology, University of Science and Technology of China) were cultured in Dulbecco's Modified Eagle Medium (Gibco; catalog number: C11995500BT) supplemented with 10% fetal bovine serum (manufacturer: Viva Cell; catalog number: C04001-500) and 1% penicillin / streptomycin (manufacturer: Viva Cell; catalog number: C3420-0100).

[0096] B. Preparation of transfection mixture: 200 ng / well of GPCR-tango plasmid (kindly provided by the Institute of Immunology, University of Science and Technology of China) was mixed with 400 ng of polyethylenimine (dissolved in 20 μL of opti-MEM) (manufacturer: Gibco; Catalog No.: 31985070) and 400 ng of polyethylenimine (manufacturer: Yisheng Biotechnology; Catalog No.: 40816ES03) (dissolved in 20 μL of opti-MEM) and incubated at room temperature for 20 minutes.

[0097] C. After the cells from step A have reached approximately 90% confluency, add the transfection mixture from step B to the cells.

[0098] D. 16-24 hours after transfection, discard the culture supernatant and add 180 μL of DMEM medium (Gibco; Catalog No.: C11995500BT) containing 1% penicillin / streptomycin and 10 mM HEPES (Pronose; Catalog No.: PB180325) and 20 μL of i) Nosocomiicoccus massiliensisibiome006 bacterial culture supernatant, ii) the positive drug, or iii) a DMEM blank control.

[0099] E. After stimulating the Nosocomiicoccus massiliensis ibiome006 bacterial culture supernatant (or positive drug or blank control) from step D for 16-24 hours, centrifuge at 1500g for 6 minutes, discard the supernatant, and add 50 μL of Bright-Glo solution (Promega; Catalog No. E2610) diluted 20-fold in PBS containing 20 mM HEPES to each well.

[0100] F. After incubation at room temperature for 20 minutes, fluorescence quantification was performed.

[0101] (3) Experimental results:

[0102] As shown in Figure 2, Nosocomiicoccus massiliensis (NM) can significantly activate GPR120, MC4R and APJ, with activation times of 7.12, 3.67 and 4.7 respectively compared with the GAM medium control.

[0103] Example 3. Nosocomiicoccus massiliensis improves obesity and related symptoms induced by high-fat diet

[0104] (1) Experimental methods:

[0105] C57BL / 6J mice (purchased from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd.) were fed a high-fat diet for 20 weeks. Mice were screened based on body weight, with an average weight of 50 g, and randomly divided into a control group and an experimental group, with 10 mice in each group. Mice in each group continued to be fed a high-fat diet while receiving medication until the end of the experiment.

[0106] The control group was gavaged with 0.2 mL of 0.9% saline per animal per day;

[0107] The experimental group was gavaged with Nosocomiicoccus massiliensisibiome006. According to the number of viable bacteria in each batch of freeze-dried bacterial powder, 10 9 The number of grams of bacterial powder required for CFU / mouse was resuspended in 0.2 mL of 0.9% saline and administered once a day;

[0108] The following experiments were carried out respectively:

[0109] a. Monitor body weight weekly;

[0110] b. Fasting blood glucose test (4 hours fast) in the fourth week of drug administration;

[0111] c. Insulin tolerance test (ITT) at week 6: Mice were fasted for 4 hours, blood glucose was measured by tail tip blood sampling (0 h), and 0.75 IU / kg insulin solution was injected subcutaneously. Blood glucose was then measured by tail tip blood sampling at 30, 60, and 120 minutes. The change in blood glucose over time was plotted, and the area under the curve was calculated.

[0112] d. Oral glucose tolerance test (OGTT) at week 7 of drug administration: Mice were fasted for 6 hours, and blood glucose was measured by tail tip blood sampling (0 h). A 2 g / kg glucose solution was then gavaged orally. Blood glucose was then measured by tail tip blood sampling at 30, 60, and 120 minutes. The blood glucose curve over time was plotted, and the area under the curve was calculated.

[0113] e. After 13 weeks of dosing, mice were fasted for 12 hours. Eyeballs were removed and blood was collected from heparin tubes. The blood was centrifuged at 4000 rpm for 10 minutes at room temperature. The supernatant plasma was transferred to a new centrifuge tube and stored at -80°C until further use. Blood glucose (Solebol; BC2505), triglyceride (Nanjing Jiancheng; A110-1-1), total cholesterol (Nanjing Jiancheng; A111-1-1), and low-density lipoprotein cholesterol (Nanjing Jiancheng; A111-1-1) levels were measured using kits.

[0114] f. After 13 weeks of dosing, mice were fasted for 12 hours, and adipose tissue (subcutaneous white fat) and liver were obtained and weighed. Then, 100 mg of liver was removed and added to 900 μL of PBS, homogenized, and centrifuged at 4000 rpm for 10 min at room temperature. The supernatant was transferred to a new centrifuge tube and stored at -80°C until further use. Kits were used to measure the levels of total cholesterol (Nanjing Jiancheng; A111-1-1), triglycerides (Nanjing Jiancheng; A110-1-1), low-density lipoprotein cholesterol (Nanjing Jiancheng; A111-1-1), and free fatty acids (Nanjing Jiancheng; A042-2-1) in the liver.

[0115] (2) Experimental results:

[0116] ① Changes in body weight during medication:

[0117] As shown in Figure 3, oral administration of the NM strain significantly inhibited the weight gain of mice. Compared with the control group, oral administration of NM significantly reduced the weight of mice starting from the second week and significantly inhibited the weight gain of mice starting from the third week.

[0118] ② Effects of drug administration on blood glucose in mice:

[0119] As shown in Figure 4, oral administration of NM can significantly reduce the fasting blood glucose (A), area under the insulin tolerance curve (B), blood glucose 30 minutes after oral glucose tolerance (C), and plasma glucose level (D) of mice, indicating that Nosocomiicoccus massiliensis can regulate blood glucose and improve insulin resistance in obese mice induced by high-fat diet.

[0120] ③ Effects of drug administration on lipid metabolism in mice:

[0121] As shown in Figure 5, oral administration of the NM strain can significantly reduce the subcutaneous fat weight (A), plasma total cholesterol level (B), plasma triglyceride level (C) and plasma low-density lipoprotein-cholesterol level (D) of mice, indicating that Nosocomiicoccus massiliensis can improve lipid metabolism levels in obese mice induced by a high-fat diet.

[0122] ④ Effects of drug administration on liver function and fatty liver in mice:

[0123] As shown in Figure 6, oral administration of NM can significantly reduce the liver weight (A), total cholesterol level in the liver (B), triglyceride level in the liver (C), low-density lipoprotein-cholesterol level in the liver (D), and free fatty acid level in the liver (E), indicating that Nosocomiicoccus massiliensis can improve the symptoms of non-alcoholic fatty liver disease in mice induced by high-fat diet.

[0124] Example 4. Nosocomiicoccus massiliensis prevents obesity and related symptoms in mice

[0125] (1) Experimental methods:

[0126] Thirty-six C57BL / 6J mice (purchased from Jiangsu Jicui Pharmaceutical Kang Biotechnology Co., Ltd.) were screened based on body weight, with an average weight of 26 g. The selected mice were randomly divided into a control group, an experimental group, and a positive drug group. All groups were fed a high-fat diet concurrently with drug administration until the end of the experiment.

[0127] The control group was gavaged with 0.2 mL of 0.9% saline per animal per day;

[0128] The experimental group was gavaged with Nosocomiicoccus massiliensisibiome006 (NM). According to the number of viable bacteria in each batch of freeze-dried bacterial powder, 10 9 The number of grams of bacterial powder required for CFU / mouse was resuspended in 0.2 mL of 0.9% saline and administered once a day;

[0129] The positive drug group received a subcutaneous injection of semaglutide (Novo Nordisk). Each mouse was given 12.8 μg / kg of semaglutide according to body weight, diluted with normal saline, and each mouse was subcutaneously injected with 0.1 mL once a week.

[0130] The following experiments were carried out respectively:

[0131] a. Monitor body weight weekly;

[0132] b. Fasting blood glucose test (6-hour fast) at week 5 of drug administration;

[0133] c. Oral glucose tolerance test (OGTT) at week 7: Mice were fasted for 6 hours, and blood glucose was measured by tail tip blood sampling (0 h). A 2 g / kg glucose solution was then gavaged orally. Blood glucose was then measured by tail tip blood sampling at 30, 60, and 120 minutes. The blood glucose curve over time was plotted, and the area under the curve was calculated.

[0134] d. Insulin tolerance test (ITT) at week 19 of drug administration: Mice were fasted for 4 hours, blood was collected from the tail tip (0 h) for blood glucose measurement, and 0.75 IU / kg insulin solution was injected subcutaneously. Blood glucose was then collected from the tail tip at 30, 60, and 120 minutes. The blood glucose change over time was plotted, and the area under the curve was calculated.

[0135] e. After 20 weeks of administration, the mice were fasted for 12 hours, and abdominal adipose tissue and liver were taken from the mice, and the abdominal adipose tissue and liver were weighed;

[0136] f. After 20 weeks of dosing, mice were fasted for 12 hours. Eyeballs were removed and blood was collected from heparin tubes. The blood was centrifuged at 4000 rpm for 10 minutes at room temperature. The supernatant plasma was transferred to a new centrifuge tube and stored at -80°C until further use. Plasma glucose (Solebo; BC2505), triglyceride (Nanjing Jiancheng; A110-1-1), and total cholesterol (Nanjing Jiancheng; A111-1-1) levels were measured using kits.

[0137] (2) Experimental results:

[0138] ① Weight changes during medication period:

[0139] As shown in FIG7 , oral administration of the NM strain can significantly inhibit the weight gain of mice, and the effect is not significantly different from that of the positive drug.

[0140] ② Effects of drug administration on blood glucose in mice:

[0141] As shown in Figure 8, oral administration of the NM strain can significantly reduce the fasting blood sugar (A) and plasma glucose content (B) of mice, and the effect is comparable to that of the positive drug; at the same time, oral administration of the NM strain can significantly reduce the area under the oral glucose tolerance curve of mice (C); in addition, oral administration of the NM strain can significantly reduce the area under the insulin curve, and the effect of the experimental group is better than that of the positive drug group (DE); this shows that for normal mice, Nosocomiicoccus massiliensis can regulate blood sugar and improve insulin resistance.

[0142] ③Effects of drug administration on lipid metabolism in mice:

[0143] As shown in Figure 9, compared with the control group, oral administration of the NM strain can significantly reduce the abdominal fat weight (A), liver weight (B), plasma total cholesterol level (C), and plasma triglyceride level (D) of mice, indicating that Nosocomiicoccus massiliensis can improve lipid metabolism levels in normal mice.

[0144] The above-described embodiments are merely descriptions of preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should fall within the scope of protection determined by the claims of the present invention. Industrial Applicability

[0145] The Nosocomiicoccus massiliensis of the present invention can significantly activate GPR120, MC4R and APJ, targets for treating obesity and diabetes; can reduce the body weight, blood sugar, lipid metabolism-related indicators (triglycerides, total cholesterol, low-density lipoprotein-cholesterol) and symptoms of non-alcoholic fatty liver disease (triglycerides, total cholesterol, low-density lipoprotein-cholesterol, free fatty acids in the liver) of obese mice, and has industrial applicability.

Claims

1. Use of a microbial strain in the preparation of a medicament for preventing or treating a metabolic disease, characterized in that: The microbial strain belongs to the species Nosocomiicoccus massiliensis, the metabolic diseases are diabetes, obesity and obesity-related diseases, and metabolic syndrome; the obesity-related diseases include at least one of the following diseases: cardiovascular disease, hyperlipidemia, insulin resistance syndrome, and fatty hepatitis.

2. The use according to claim 1, characterized in that The drug is used for at least one of the following purposes: Prevent or treat obesity-induced diabetes; Prevent or treat type 2 diabetes; Activation of GPR120, MC4R and / or APJ; Reducing the weight of mammals; Reducing adipose tissue and / or liver weight in a mammal; Lowering fasting blood sugar in mammals; Lowers plasma glucose in mammals; Decreases the area under the oral glucose tolerance curve in mammals; Reduces the area under the insulin tolerance curve in mammals; Improve abnormal insulin sensitivity in mammals; Reducing the level of at least one of the following indicators in the blood of a mammal: total cholesterol, triglycerides, low-density lipoprotein-cholesterol; Reducing the level of at least one of the following indicators in the liver of a mammal: total cholesterol, triglycerides, low-density lipoprotein-cholesterol, and free fatty acids.

3. The use according to claim 1, characterized in that: The microbial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 98.65%, 99%, 99.5%, 99.63%, 99.9%, or 100% identical to SEQ ID NO: 1 or 2.

4. The use according to claim 1, characterized in that: The medicament further comprises pharmaceutically acceptable excipients, carriers, auxiliary materials and / or vehicles.

5. The use according to claim 1 or 4, characterized in that: The drug also includes other drugs that act synergistically with Nosocomiicoccus massiliensis.

6. The use according to claim 1, characterized in that: The microbial strain is the Nosocomiicoccus massiliensisibiome006 strain or its progeny strain or subclone strain preserved with the preservation number CCTCC NO: M 2023697. The Nosocomiicoccus massiliensisibiome006 strain is deposited in the China Center for Type Culture Collection, the address is China Center for Type Culture Collection, Wuhan University, Bayi Road, Wuchang District, Wuhan City, Hubei Province, and the preservation date is May 6, 2023.

7. Nosocomiicoccus massiliensis ibiome006 strain deposited with CCTCC NO: M 2023697 or its progeny strain or subclone strain.

8. A drug, characterized in that: Comprising the strain according to claim 7 and a pharmaceutically acceptable excipient, carrier, auxiliary material and / or vehicle.

9. A pharmaceutical composition, characterized in that: A method comprising the strain according to claim 7 and a combined drug, wherein the combined drug is another drug that has a synergistic effect with Nosocomiicoccus massiliensis; Preferably, the combined drug is an active ingredient of other glucose-lowering and lipid-lowering drugs, such as GLP-1 receptor agonists, GLP-1 analog drugs, biguanide drugs, etc.

10. A fermentation agent, a functional bacterial agent or a nutritional composition comprising the strain according to claim 7; preferably, the nutritional composition is a food, a nutrient, a supplement, a probiotic or a symbiotic bacteria.

Citation Information

Patent Citations

  • Application of quinoline derivative in preparation of medicine for treating diabetes and complications thereof

    CN113599382A

  • Bifidobacterium bifidum for treating diabetes and related conditions

    CN115948273A

  • Use of microbial strains for preparation of medicament for prevention or treatment of metabolic diseases

    CN118021848A

  • Methods and compositions for treating and preventing central nervous system disorders and other conditions caused by gut microbial dysbiosis

    US20220096574A1

  • Combination of bitter receptor agonist and gut-signaling compound

    WO2022232168A1